The Medicines Stock Price, News & Analysis (NASDAQ:MDCO)

$31.07 +1.24 (+4.16 %)
(As of 02/23/2018 04:00 PM ET)
Previous Close$31.07
Today's Range$29.32 - $32.07
52-Week Range$24.45 - $55.95
Volume1.39 million shs
Average Volume1.77 million shs
Market Capitalization$2.36 billion
P/E Ratio-3.25
Dividend YieldN/A
Beta0.69

About The Medicines (NASDAQ:MDCO)

The Medicines logoThe Medicines Company is a global biopharmaceutical company. The Company is focused on advancing the treatment of acute and intensive care patients through the delivery of medicines to the hospital marketplace around the world. It markets Angiomax (bivalirudin), Ionsys (fentanyl iontophoretic transdermal system), Minocin (minocycline) for injection and Orbactiv (oritavancin). It also has a pipeline of products in development, including Carbavance, inclisiran and MDCO-700. Carbavance is used for the treatment of hospitalized patients with gram-negative bacterial infections. Inclisiran is used for the treatment of hypercholesterolemia. MDCO-700 includes sedative-hypnotic, which is used to induce and maintain sedation for procedural care and general anesthesia for surgical care. In addition to these products and products in development, it has a portfolio of generic drugs.

Receive MDCO News and Ratings via Email

Sign-up to receive the latest news and ratings for MDCO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Generic Pharmaceuticals
Sub-IndustryPharmaceuticals
SectorHealthcare
SymbolNASDAQ:MDCO
CUSIP58468810
Phone+1-973-2906000

Debt

Debt-to-Equity Ratio3.42%
Current Ratio2.31%
Quick Ratio1.79%

Price-To-Earnings

Trailing P/E Ratio-3.2466039707419
Forward P/E Ratio-11.06
P/E GrowthN/A

Sales & Book Value

Annual Sales$44.79 million
Price / Sales50.57
Cash FlowN/A
Price / CashN/A
Book Value$9.21 per share
Price / Book3.37

Profitability

Trailing EPS($9.57)
Net Income$-119,110,000.00
Net Margins-1,035.27%
Return on Equity-244.28%
Return on Assets-55.18%

Miscellaneous

Employees410
Outstanding Shares72,900,000

The Medicines (NASDAQ:MDCO) Frequently Asked Questions

What is The Medicines' stock symbol?

The Medicines trades on the NASDAQ under the ticker symbol "MDCO."

How were The Medicines' earnings last quarter?

The Medicines Company (NASDAQ:MDCO) released its earnings results on Wednesday, February, 21st. The company reported ($2.19) EPS for the quarter, missing the Zacks' consensus estimate of ($1.48) by $0.71. The business had revenue of $8.60 million for the quarter, compared to the consensus estimate of $20.71 million. The Medicines had a negative return on equity of 244.28% and a negative net margin of 1,035.27%. The company's revenue for the quarter was down 50.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($1.19) earnings per share. View The Medicines' Earnings History.

When will The Medicines make its next earnings announcement?

The Medicines is scheduled to release their next quarterly earnings announcement on Wednesday, April, 25th 2018. View Earnings Estimates for The Medicines.

Where is The Medicines' stock going? Where will The Medicines' stock price be in 2018?

9 equities research analysts have issued twelve-month target prices for The Medicines' stock. Their predictions range from $40.00 to $85.00. On average, they anticipate The Medicines' stock price to reach $52.89 in the next year. View Analyst Ratings for The Medicines.

What are Wall Street analysts saying about The Medicines stock?

Here are some recent quotes from research analysts about The Medicines stock:

  • 1. According to Zacks Investment Research, "The Medicines Co. has a blockbuster candidate, Inclisiran, in its pipeline. We also await a clearer picture of the commercial potential of Inclisiran, if approved. Moreover, The Medicines Co. has undertaken restructuring program to boost shareholder value. We are also encouraged by the company’s regular divesture of non-core products. This would help the company to optimize its capital structure and enhance its liquidity position. However, with Angiomax sales eroding due to presence of generics, the company’s ability to successfully develop and bring new products to the market is important for growth. Any regulatory setbacks would weigh heavily on the stock. The company’s shares have underperformed the industry in the last one year. Estimates have been stable lately ahead of the company’s Q4 earnings release. The company has negative record of earnings surprises in recent quarters." (2/6/2018)
  • 2. Chardan Capital analysts commented, "We found particularly notable: (1) MDCO completing recruitment in just 11 weeks for its 1500-patient ORION-11 pivotal phase III trial of siRNA- based PSCK9 synthesis inhibitor inclisiran (partnered with Alnylam, Buy) and may thus have its first top-line pivotal results in 3Q19, (2) the confirmation commercial scale manufacturing for inclisiran has been achieved, and (3) new inclisiran efficacy data in HoFH to us suggesting efficacy beyond mAb PCSK9 inhibitors. With inclisiran to us having clear momentum towards 2H19E pivotal data and what we expect will be $4.7 billion in 2030E peak sales, we make MDCO a Chardan Top Pick for 2018." (1/24/2018)
  • 3. Jefferies Group LLC analysts commented, " ACC (Mar 17-19) will be a key meeting for inclisiran, where MDCO will detail full 6-mo data for ORION-1 and AMGN will present the FOURIER data. Data from the latter should help guide PIII development for inclisiran, for which MDCO continues to seek a partner. On positive FOURIER results, we lower our risk-discount on inclisiran and our PT increases to $62 (v. $49 prev)." (3/1/2017)

Who are some of The Medicines' key competitors?

Who are The Medicines' key executives?

The Medicines' management team includes the folowing people:

  • Fredric N. Eshelman Ph.D., Executive Chairman of the Board (Age 68)
  • Clive A. Meanwell Ph.D., Chief Executive Officer, Director (Age 59)
  • William Bernard O'Connor, Chief Financial Officer (Age 58)
  • Christopher T. Cox, Executive Vice President, Chief Corporate Development Officer (Age 52)
  • Jeffrey Frazier, Executive Vice President, Chief Human Strategy Officer (Age 54)
  • Stephen M. Rodin J.D., General Counsel, Secretary (Age 41)
  • Paris Panayiotopoulos, Director (Age 43)
  • William W. Crouse, Independent Director (Age 74)
  • Alexander J. Denner Ph.D., Independent Director (Age 47)
  • Geno J. Germano, Independent Director (Age 56)

Who owns The Medicines stock?

The Medicines' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Iridian Asset Management LLC CT (2.98%), Franklin Resources Inc. (2.82%), Sarissa Capital Management LP (2.64%), Slate Path Capital LP (2.37%), Alliancebernstein L.P. (1.75%) and Pinnacle Associates Ltd. (1.60%). Company insiders that own The Medicines stock include Alexander J Denner, Armin M Kessler, Christopher T Cox, Clive Meanwell, Elizabeth H S Wyatt, Fredric N Eshelman, Hiroaki Shigeta, Melvin K Spigelman, William Bernard O'connor and William Crouse. View Institutional Ownership Trends for The Medicines.

Who sold The Medicines stock? Who is selling The Medicines stock?

The Medicines' stock was sold by a variety of institutional investors in the last quarter, including Teachers Retirement System of The State of Kentucky, KBC Group NV, Pinnacle Associates Ltd., Creative Planning, Iguana Healthcare Management LLC, Alliancebernstein L.P., BlueCrest Capital Management Ltd and Metropolitan Life Insurance Co. NY. View Insider Buying and Selling for The Medicines.

Who bought The Medicines stock? Who is buying The Medicines stock?

The Medicines' stock was bought by a variety of institutional investors in the last quarter, including Slate Path Capital LP, Carillon Tower Advisers Inc., Iridian Asset Management LLC CT, Broadfin Capital LLC, Millennium Management LLC, Sarissa Capital Management LP, Teachers Advisors LLC and University of Notre Dame DU Lac. Company insiders that have bought The Medicines stock in the last two years include Alexander J Denner, Christopher T Cox and Fredric N Eshelman. View Insider Buying and Selling for The Medicines.

How do I buy The Medicines stock?

Shares of The Medicines can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is The Medicines' stock price today?

One share of The Medicines stock can currently be purchased for approximately $31.07.

How big of a company is The Medicines?

The Medicines has a market capitalization of $2.36 billion and generates $44.79 million in revenue each year. The company earns $-119,110,000.00 in net income (profit) each year or ($9.57) on an earnings per share basis. The Medicines employs 410 workers across the globe.

How can I contact The Medicines?

The Medicines' mailing address is 8 SYLVAN WAY, PARSIPPANY, NJ 07054, United States. The company can be reached via phone at +1-973-2906000 or via email at [email protected]


MarketBeat Community Rating for The Medicines (MDCO)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  365 (Vote Outperform)
Underperform Votes:  225 (Vote Underperform)
Total Votes:  590
MarketBeat's community ratings are surveys of what our community members think about The Medicines and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

The Medicines (NASDAQ:MDCO) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.893.002.782.80
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $52.89$53.67$55.25$53.22
Price Target Upside: 70.22% upside76.13% upside70.58% upside50.35% upside

The Medicines (NASDAQ:MDCO) Consensus Price Target History

Price Target History for The Medicines (NASDAQ:MDCO)

The Medicines (NASDAQ:MDCO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/23/2018Jefferies GroupReiterated RatingBuy$47.00N/AView Rating Details
2/22/2018OppenheimerSet Price TargetHold$50.00HighView Rating Details
1/24/2018Chardan CapitalReiterated RatingBuy$85.00HighView Rating Details
1/24/2018JPMorgan Chase & Co.Reiterated RatingOverweight -> Overweight$45.00HighView Rating Details
1/22/2018CitigroupUpgradeNeutral -> Buy$40.00HighView Rating Details
10/23/2017GuggenheimInitiated CoverageBuy$45.00N/AView Rating Details
8/10/2017CowenReiterated RatingBuy$61.00 -> $54.00HighView Rating Details
5/23/2017CIBCSet Price Target$50.00MediumView Rating Details
3/20/2017HC WainwrightReiterated RatingBuy$60.00HighView Rating Details
3/1/2017Royal Bank of CanadaReiterated RatingBuyN/AView Rating Details
11/8/2016Leerink SwannReiterated RatingOutperform$53.00 -> $50.00N/AView Rating Details
7/12/2016Bank of AmericaReiterated RatingBuyN/AView Rating Details
(Data available from 2/24/2016 forward)

Earnings

The Medicines (NASDAQ:MDCO) Earnings History and Estimates Chart

Earnings by Quarter for The Medicines (NASDAQ:MDCO)

The Medicines (NASDAQ MDCO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/24/2018($0.82)N/AView Earnings Details
2/21/2018Q4 2017($1.48)($2.19)$20.71 million$8.60 millionViewListenView Earnings Details
10/25/2017Q3 2017($1.37)($0.42)$26.06 million$16.87 millionViewN/AView Earnings Details
8/9/2017Q2 2017($1.29)($5.52)$29.64 million$18.74 millionViewListenView Earnings Details
4/26/2017Q1 2017($1.13)($1.44)$37.76 million$24.20 millionViewN/AView Earnings Details
2/28/2017Q416($1.43)($1.29)$26.91 million$25.20 millionViewListenView Earnings Details
10/26/2016Q316($1.38)($0.64)$37.26 million$37.60 millionViewListenView Earnings Details
7/27/2016Q216($1.16)($0.62)$41.93 million$54.70 millionViewListenView Earnings Details
5/9/2016Q116($0.89)($1.03)$48.96 million$50.30 millionViewListenView Earnings Details
2/17/2016Q415($1.54)($0.88)$64.11 million$67.20 millionViewN/AView Earnings Details
11/3/2015Q315($0.88)($0.90)$68.58 million$72.70 millionViewListenView Earnings Details
7/29/2015Q215($0.20)($0.74)$122.58 million$90.50 millionViewListenView Earnings Details
5/5/2015Q115($0.68)($0.02)$138.78 million$126.50 millionViewListenView Earnings Details
2/18/2015Q414($0.84)$0.11$188.55 million$191.00 millionViewListenView Earnings Details
10/22/2014Q314($0.10)$0.10$188.30 million$172.40 millionViewListenView Earnings Details
7/23/2014Q214($0.07)$0.22$183.75 million$183.80 millionViewListenView Earnings Details
4/23/2014Q114($0.13)$0.22$175.60 million$177.20 millionViewListenView Earnings Details
2/19/2014Q413$0.11$0.26$182.60 million$185.00 millionViewListenView Earnings Details
10/23/2013Q313$0.24$0.47$173.86 million$173.45 millionViewListenView Earnings Details
7/24/2013Q2 2013$0.33$0.50$168.70 million$172.00 millionViewListenView Earnings Details
4/24/2013Q1 2013($0.26)$0.31$152.63 million$155.80 millionViewListenView Earnings Details
2/20/2013Q4 2012$0.28$0.38$146.09 million$159.50 millionViewListenView Earnings Details
10/24/2012$0.39$0.40ViewN/AView Earnings Details
7/25/2012$0.22$0.46ViewN/AView Earnings Details
4/25/2012$0.14$0.27ViewN/AView Earnings Details
2/22/2012$0.24$0.52ViewN/AView Earnings Details
10/26/2011$0.20$0.17ViewN/AView Earnings Details
7/27/2011$0.31$0.21ViewN/AView Earnings Details
4/27/2011$0.40$0.45ViewN/AView Earnings Details
2/16/2011$0.24$0.30ViewN/AView Earnings Details
10/27/2010Q3 2010$0.24$0.40ViewN/AView Earnings Details
7/28/2010Q2 2010$0.23$0.29ViewN/AView Earnings Details
4/28/2010Q1 2010$0.13$0.19ViewN/AView Earnings Details
2/15/2010Q4 2009($1.40)ViewN/AView Earnings Details
10/28/2009Q3 2009($0.05)($0.06)ViewN/AView Earnings Details
7/29/2009Q2 2009$0.05$0.07ViewN/AView Earnings Details
4/29/2009Q1 2009($0.03)($0.04)ViewN/AView Earnings Details
2/18/2009Q4 2008$0.03($0.08)ViewN/AView Earnings Details
7/23/2008Q2 2008$0.07$0.08ViewN/AView Earnings Details
4/23/2008Q1 2008$0.06$0.09ViewN/AView Earnings Details
2/13/2008Q4 2007$0.02$0.03ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

The Medicines (NASDAQ:MDCO) Earnings Estimates

2018 EPS Consensus Estimate: ($2.75)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183($1.02)($0.55)($0.82)
Q2 20183($0.94)($0.56)($0.81)
Q3 20183($0.78)($0.38)($0.57)
Q4 20183($0.72)($0.37)($0.56)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for The Medicines (NASDAQ:MDCO)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

The Medicines (NASDAQ MDCO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 8.22%
Insider Trades by Quarter for The Medicines (NASDAQ:MDCO)
Institutional Ownership by Quarter for The Medicines (NASDAQ:MDCO)

The Medicines (NASDAQ MDCO) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/15/2017Clive MeanwellCEOSell136,250$27.24$3,711,450.00587,652View SEC Filing  
12/8/2017Fredric N EshelmanInsiderBuy200,000$26.56$5,312,000.001,028,383View SEC Filing  
11/29/2017Alexander J DennerDirectorBuy170,000$30.03$5,105,100.006,663View SEC Filing  
2/7/2017William Bernard O'connorCFOSell25,833$46.20$1,193,484.6030,935View SEC Filing  
12/8/2016Christopher T CoxEVPBuy105,500$33.20$3,502,600.0033,670View SEC Filing  
12/8/2016Fredric N EshelmanDirectorBuy621,720$33.77$20,995,484.40641,106View SEC Filing  
9/21/2016Clive MeanwellCEOSell8,623$40.00$344,920.00347,791View SEC Filing  
9/1/2016Clive MeanwellCEOSell1,377$40.00$55,080.00339,168View SEC Filing  
8/24/2016Clive MeanwellCEOSell20,000$40.00$800,000.00358,790View SEC Filing  
7/11/2016Hiroaki ShigetaDirectorSell3,849$38.50$148,186.5023,547View SEC Filing  
6/10/2016Christopher T CoxEVPBuy45,985$37.90$1,742,831.5033,670View SEC Filing  
6/7/2016Christopher T CoxEVPBuy53,340$37.55$2,002,917.0020,800View SEC Filing  
5/24/2016Melvin K SpigelmanDirectorSell15,000$37.00$555,000.0053,970View SEC Filing  
5/16/2016Clive MeanwellCEOSell10,000$35.00$350,000.00348,790View SEC Filing  
5/16/2016William CrouseDirectorSell15,000$35.15$527,250.0053,970View SEC Filing  
5/13/2016Elizabeth H S WyattDirectorSell15,000$34.07$511,050.0049,817View SEC Filing  
5/12/2016Fredric N EshelmanDirectorBuy300,000$33.68$10,104,000.00300,000View SEC Filing  
3/7/2016Armin M KesslerDirectorSell8,100$34.82$282,042.00144,930View SEC Filing  
11/13/2015Robert G. SavageDirectorSell5,000$39.34$196,700.0027,720View SEC Filing  
9/3/2015Glenn SblendorioCFOSell25,000$42.00$1,050,000.0099,805View SEC Filing  
8/31/2015Clive MeanwellCEOSell49,998$39.36$1,967,921.28324,905View SEC Filing  
8/31/2015Glenn SblendorioCFOSell114,495$39.75$4,551,176.2599,805View SEC Filing  
8/31/2015Melvin K. SpigelmanDirectorSell20,000$40.50$810,000.0038,970View SEC Filing  
8/31/2015William Bernard O'connorSVPSell35,451$40.00$1,418,040.0024,732View SEC Filing  
7/1/2015Clive MeanwellCEOSell16,667$28.39$473,176.13View SEC Filing  
6/25/2015Glenn SblendorioCFOSell3,305$32.00$105,760.00View SEC Filing  
6/8/2015Hiroaki ShigetaDirectorSell7,500$28.99$217,425.00View SEC Filing  
5/20/2015Robert G SavageDirectorSell15,000$26.78$401,700.00View SEC Filing  
4/16/2015William Bernard O'connorSVPSell1,281$30.00$38,430.00View SEC Filing  
4/1/2015Clive MeanwellCEOSell16,667$27.58$459,675.86View SEC Filing  
3/30/2015Elizabeth H S WyattDirectorSell20,000$28.08$561,600.00View SEC Filing  
3/23/2015Clive MeanwellCEOSell16,667$30.62$510,343.54View SEC Filing  
3/23/2015Glenn SblendorioCFOSell34,773$30.78$1,070,312.94View SEC Filing  
3/2/2015William Bernard O'connorSVPSell2,988$28.78$85,994.64View SEC Filing  
3/3/2014William Bernard O'connorSVPSell2,968$30.31$89,960.0827,870View SEC Filing  
1/21/2014Paul Michael AntinoriVPSell37,883$38.02$1,440,311.6631,029View SEC Filing  
1/15/2014William Bernard O'connorSVPSell4,427$39.15$173,317.0525,058View SEC Filing  
1/10/2014William Bernard O'connorSVPSell72,384$40.00$2,895,360.0025,058View SEC Filing  
1/7/2014Clive MeanwellCEOSell27,929$38.13$1,064,932.77297,773View SEC Filing  
1/3/2014Clive MeanwellCEOSell57,516$38.16$2,194,810.56297,773View SEC Filing  
12/9/2013William CrouseDirectorSell12,500$38.00$475,000.0029,849View SEC Filing  
12/5/2013Glenn SblendorioCFOSell8,516$38.50$327,866.00118,405View SEC Filing  
12/2/2013Clive MeanwellCEOSell10,000$36.58$365,800.00307,773View SEC Filing  
11/26/2013Clive MeanwellCEOSell135,000$36.70$4,954,500.00317,773View SEC Filing  
10/23/2013William Bernard O'connorSVPSell6,354$35.00$222,390.00View SEC Filing  
9/13/2013Paul Michael AntinoriVPSell73,500$34.50$2,535,750.0051,906View SEC Filing  
9/3/2013Clive MeanwellCEOSell7,500$31.85$238,875.00View SEC Filing  
8/1/2013Clive MeanwellCEOSell7,500$31.26$234,450.00View SEC Filing  
7/8/2013Paul Michael AntinoriVPSell36,000$33.00$1,188,000.00View SEC Filing  
7/1/2013Clive MeanwellCEOSell7,500$31.25$234,375.00View SEC Filing  
6/11/2013Paul Michael AntinoriVPSell109,973$33.29$3,661,001.17View SEC Filing  
5/29/2013Armin M KesslerDirectorSell8,750$33.05$289,187.50View SEC Filing  
5/10/2013Glenn SblendorioCFOSell2,709$37.00$100,233.00View SEC Filing  
5/9/2013Paul Michael AntinoriVPSell35,000$34.90$1,221,500.00View SEC Filing  
5/9/2013William Bernard O'connorSVPSell29,654$35.00$1,037,890.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

The Medicines (NASDAQ MDCO) News Headlines

Source:
DateHeadline
KBC Group NV Has $1.42 Million Stake in The Medicines Company (MDCO)KBC Group NV Has $1.42 Million Stake in The Medicines Company (MDCO)
www.americanbankingnews.com - February 24 at 5:24 AM
Jefferies Group Weighs in on The Medicines Companys FY2022 Earnings (MDCO)Jefferies Group Weighs in on The Medicines Company's FY2022 Earnings (MDCO)
www.americanbankingnews.com - February 23 at 5:22 PM
Medicines Company (MDCO) Reports Q4 Loss, Revenues Slump Y/YMedicines Company (MDCO) Reports Q4 Loss, Revenues Slump Y/Y
finance.yahoo.com - February 22 at 5:08 PM
The Medicines (MDCO) CEO Clive Meanwell on Q4 2017 Results - Earnings Call TranscriptThe Medicines' (MDCO) CEO Clive Meanwell on Q4 2017 Results - Earnings Call Transcript
seekingalpha.com - February 21 at 5:08 PM
The Medicines Company (MDCO) Receives Average Rating of "Buy" from AnalystsThe Medicines Company (MDCO) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - February 21 at 2:30 PM
The Medicines (MDCO) Announces Quarterly  Earnings ResultsThe Medicines (MDCO) Announces Quarterly Earnings Results
www.americanbankingnews.com - February 21 at 11:24 AM
Earnings Reaction History: The Medicines Company, 37.5% Follow-Through Indicator, 4.1% SensitiveEarnings Reaction History: The Medicines Company, 37.5% Follow-Through Indicator, 4.1% Sensitive
www.nasdaq.com - February 21 at 9:28 AM
Medicines Company to Host Earnings CallMedicines Company to Host Earnings Call
finance.yahoo.com - February 21 at 9:28 AM
Blueprint Medicines Reports Fourth Quarter and Full Year 2017 Financial ResultsBlueprint Medicines Reports Fourth Quarter and Full Year 2017 Financial Results
www.prnewswire.com - February 21 at 7:27 AM
The Medicines (MDCO) to Release Quarterly Earnings on WednesdayThe Medicines (MDCO) to Release Quarterly Earnings on Wednesday
www.americanbankingnews.com - February 16 at 12:14 AM
The Medicines Company to Host Conference Call and Webcast Discussing Fourth-Quarter and Full-Year 2017 Financial ResultsThe Medicines Company to Host Conference Call and Webcast Discussing Fourth-Quarter and Full-Year 2017 Financial Results
finance.yahoo.com - February 15 at 6:57 AM
Oracle Argus Supports E2B(R3) Exchange with the European Medicines Agencys Enhanced EudraVigilance SystemOracle Argus Supports E2B(R3) Exchange with the European Medicines Agency's Enhanced EudraVigilance System
www.prnewswire.com - February 13 at 5:10 AM
Zacks: Brokerages Anticipate The Medicines Company (MDCO) Will Announce Quarterly Sales of $20.31 MillionZacks: Brokerages Anticipate The Medicines Company (MDCO) Will Announce Quarterly Sales of $20.31 Million
www.americanbankingnews.com - February 11 at 4:12 AM
 Analysts Expect The Medicines Company (MDCO) to Announce -$1.48 EPS Analysts Expect The Medicines Company (MDCO) to Announce -$1.48 EPS
www.americanbankingnews.com - February 9 at 7:12 PM
Alnylams (ALNY) Q4 Earnings and Revenues Top EstimatesAlnylam's (ALNY) Q4 Earnings and Revenues Top Estimates
finance.yahoo.com - February 9 at 3:33 PM
Alnylam's (ALNY) Q4 Earnings and Revenues Top EstimatesAlnylam's (ALNY) Q4 Earnings and Revenues Top Estimates
finance.yahoo.com - February 9 at 3:33 PM
The Medicines Company to Participate in the Leerink Partners 7th Annual Global Healthcare ConferenceThe Medicines Company to Participate in the Leerink Partners 7th Annual Global Healthcare Conference
finance.yahoo.com - February 9 at 6:54 AM
Naming Tool for Biologic Medicines Released; Ensures Compliance with FDA, WHO StandardsNaming Tool for Biologic Medicines Released; Ensures Compliance with FDA, WHO Standards
www.prnewswire.com - February 8 at 7:49 PM
3 Top Cholesterol Drug Stocks to Consider Buying Now -- The ... - Motley Fool3 Top Cholesterol Drug Stocks to Consider Buying Now -- The ... - Motley Fool
www.fool.com - February 8 at 6:45 AM
Atlassian, AeroVironment, Granite Construction: Mad Money Lightning RoundAtlassian, AeroVironment, Granite Construction: 'Mad Money' Lightning Round
www.thestreet.com - February 7 at 6:51 AM
The Medicines (MDCO) Raised to "Buy" at Zacks Investment ResearchThe Medicines (MDCO) Raised to "Buy" at Zacks Investment Research
www.americanbankingnews.com - February 6 at 12:51 PM
The Medicines (MDCO) Cut to Hold at Zacks Investment ResearchThe Medicines (MDCO) Cut to Hold at Zacks Investment Research
www.americanbankingnews.com - February 2 at 12:44 PM
Sanofi: Sanofi, DNDi seek European Medicines Agency  review for sleeping sickness treatmentSanofi: Sanofi, DNDi seek European Medicines Agency review for sleeping sickness treatment
feeds.benzinga.com - January 31 at 2:51 AM
The Medicines (MDCO) Overweight Rating Reaffirmed at JPMorgan Chase & Co.The Medicines' (MDCO) Overweight Rating Reaffirmed at JPMorgan Chase & Co.
www.americanbankingnews.com - January 28 at 5:34 PM
The Medicines (MDCO) Raised to Sell at BidaskClubThe Medicines (MDCO) Raised to Sell at BidaskClub
www.americanbankingnews.com - January 28 at 7:52 AM
The Medicines Company (MDCO) Receives Average Rating of "Buy" from BrokeragesThe Medicines Company (MDCO) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - January 27 at 2:12 PM
Leerink Swann Equities Analysts Increase Earnings Estimates for The Medicines Company (MDCO)Leerink Swann Equities Analysts Increase Earnings Estimates for The Medicines Company (MDCO)
www.americanbankingnews.com - January 26 at 7:52 AM
Inclisiran’s First Pivotal Trial Achieves Target Enrollment Ahead of ScheduleInclisiran’s First Pivotal Trial Achieves Target Enrollment Ahead of Schedule
www.businesswire.com - January 26 at 6:44 AM
The Medicines Company Forecasted to Post FY2020 Earnings of ($1.47) Per Share (MDCO)The Medicines Company Forecasted to Post FY2020 Earnings of ($1.47) Per Share (MDCO)
www.americanbankingnews.com - January 25 at 4:02 PM
Medicines Co. (MDCO) Says Inclisirans First Pivotal Trial Achieves ... - StreetInsider.comMedicines Co. (MDCO) Says Inclisiran's First Pivotal Trial Achieves ... - StreetInsider.com
www.streetinsider.com - January 25 at 3:26 PM
CORRECTING and REPLACING Inclisiran’s First Pivotal Trial Achieves Target Enrollment Ahead of ScheduleCORRECTING and REPLACING Inclisiran’s First Pivotal Trial Achieves Target Enrollment Ahead of Schedule
finance.yahoo.com - January 25 at 3:26 PM
Why The Medicinces Company Is Having an Outstanding WeekWhy The Medicinces Company Is Having an Outstanding Week
finance.yahoo.com - January 25 at 6:48 AM
The Medicines Company (MDCO) Expected to Announce Quarterly Sales of $20.38 MillionThe Medicines Company (MDCO) Expected to Announce Quarterly Sales of $20.38 Million
www.americanbankingnews.com - January 25 at 2:16 AM
Medicines Co. (MDCO): Top Pick for 2018 - Chardan - StreetInsider.comMedicines Co. (MDCO): Top Pick for 2018 - Chardan - StreetInsider.com
www.streetinsider.com - January 24 at 3:30 PM
Medicines Company continues inclisiran-stoked rally, shares ahead 8% - Seeking AlphaMedicines Company continues inclisiran-stoked rally, shares ahead 8% - Seeking Alpha
seekingalpha.com - January 24 at 3:30 PM
The Medicines (MDCO) Given "Buy" Rating at Chardan CapitalThe Medicines (MDCO) Given "Buy" Rating at Chardan Capital
www.americanbankingnews.com - January 24 at 9:50 AM
The Medicines Company (MDCO) Expected to Announce Earnings of -$1.48 Per ShareThe Medicines Company (MDCO) Expected to Announce Earnings of -$1.48 Per Share
www.americanbankingnews.com - January 23 at 9:26 PM
The Medicines Cos inclisiran an Orphan Drug in US for HoFH; shares up 3% - Seeking AlphaThe Medicines Co's inclisiran an Orphan Drug in US for HoFH; shares up 3% - Seeking Alpha
seekingalpha.com - January 23 at 3:31 PM
The Week Ahead: IPOs, Earnings, And FDA Actions Provide CatalystsThe Week Ahead: IPOs, Earnings, And FDA Actions Provide Catalysts
feeds.benzinga.com - January 22 at 3:45 PM
The Medicines (MDCO) versus Hospira (HSP) Critical SurveyThe Medicines (MDCO) versus Hospira (HSP) Critical Survey
www.americanbankingnews.com - January 15 at 3:32 AM
TiGenix announces publication in Gastroenterology of 52-week results of the Phase III ADMIRE-CD trial of Cx601TiGenix announces publication in Gastroenterology of 52-week results of the Phase III ADMIRE-CD trial of Cx601
feeds.benzinga.com - January 15 at 2:14 AM
Hospira (HSP) vs. The Medicines (MDCO) Financial ReviewHospira (HSP) vs. The Medicines (MDCO) Financial Review
www.americanbankingnews.com - January 13 at 1:06 AM
Is the Options Market Predicting a Spike in Medicines Company (MDCO) Stock?Is the Options Market Predicting a Spike in Medicines Company (MDCO) Stock?
finance.yahoo.com - January 11 at 9:36 AM
Reviewing Hospira (HSP) and The Medicines (MDCO)Reviewing Hospira (HSP) and The Medicines (MDCO)
www.americanbankingnews.com - January 11 at 8:16 AM
Helsinn Group and MEI Pharma Announce that Pracinostat has Received Orphan Drug Designation from the European Medicines Agency for the Treatment of Acute Myeloid Leukemia (AML)Helsinn Group and MEI Pharma Announce that Pracinostat has Received Orphan Drug Designation from the European Medicines Agency for the Treatment of Acute Myeloid Leukemia (AML)
www.prnewswire.com - January 11 at 4:33 AM
Active-Investors: Blog Exposure - The Medicines Co. Completes Divestiture of Infectious Disease Business Unit to Melinta TherapeuticsActive-Investors: Blog Exposure - The Medicines Co. Completes Divestiture of Infectious Disease Business Unit to Melinta Therapeutics
www.finanznachrichten.de - January 10 at 9:23 AM
Hospira (HSP) & The Medicines (MDCO) Critical ReviewHospira (HSP) & The Medicines (MDCO) Critical Review
www.americanbankingnews.com - January 10 at 8:02 AM
Mallinckrodt (MNK) to Sell Recothrom and Preveleak to BaxterMallinckrodt (MNK) to Sell Recothrom and Preveleak to Baxter
finance.yahoo.com - January 9 at 9:22 AM
The Medicines Company Announces Closing of Divestiture of Infectious Disease Business Unit to Melinta TherapeuticsThe Medicines Company Announces Closing of Divestiture of Infectious Disease Business Unit to Melinta Therapeutics
finance.yahoo.com - January 8 at 5:35 PM
The Medicines Company Announces Closing of Divestiture of Infectious Disease Business Unit to Melinta Therapeutics - Business Wire (press release)The Medicines Company Announces Closing of Divestiture of Infectious Disease Business Unit to Melinta Therapeutics - Business Wire (press release)
www.businesswire.com - January 8 at 8:20 AM

SEC Filings

The Medicines (NASDAQ:MDCO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

The Medicines (NASDAQ:MDCO) Income Statement, Balance Sheet and Cash Flow Statement

Chart

The Medicines (NASDAQ MDCO) Stock Chart for Saturday, February, 24, 2018

Loading chart…

This page was last updated on 2/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.